Journal of Analytical & Bioanalytical Techniques
Open Access

Abstract

Antidepressants are the drugs, used to treat depression, thereby, elevates mood and modifies the behaviour. Depression still remains a common devastating disorder worldwide; treatment of depression is gaining importance in recent years. Elaborate research work has been carried out in the past and continuing in the present to synthesize new compounds to meet this depression. In this method iminodibenzyl was treated with 3-chloro-propyl-dimethyl amine in presence of toluene to get [3-(10,11-dihydro- dibenz [b, f] azepin-5-yl)- propyl]-dimethylamine, which was treated with ethyl chloro formate to get [3-(10,11-dihydro-dibenz [b,f] azepin-5-yl)- propyl]-methyl-carbamic acid ethyl ester, which upon hydrolysis in presence of KOH to get [3-(10,11-dihydro- dibenz [b, f] azepin-5-yl)propyl]-methylamine, which was substituted with various substituents to give corresponding derivatives. The yields of all synthesized compounds (DP-01- DP-14) were found to be in the range of 62-87%. TLC, IR and NMR spectral studies confirmed structure of derivatives. The synthesized derivatives were screened for antidepressant activity by determining immobility time in mice by despair swim test. Derivatives DP-01/03, DP-03/01, DP-04/05, DP-06/02, DP-07/03 & DP-08/01 were shown less immobility time. Derivatives DP-03/01 & DP-07/03 were shown high immobility time. The results were expressed as mean ± SEM and ANOVA followed by Dunnett test was used to evaluate statistical significance. All derivatives had shown significant activity compared to that of standard drug i.e. imipramine and control.

Biography

Deepak Sahu is an Assistant Professor of Pharmaceutics at the Geetanjali University, Udaipur, Rajasthan, India. He received his double doctorate in Alternative Medicine & Pharmaceutical Sciences from Alternative Medical Council, Calcutta & Rajasthan University of Health Sciences, Jaipur. He is editorial member & reviewer of many national & international journals. His research interests include the formulation development of newer dosage forms. He has received two fellowship FRHS & MRHS form reputed organizations